Trevi Therapeutics, Inc. (NASDAQ:TRVI) to Post FY2024 Earnings of ($0.46) Per Share, Leerink Partnrs Forecasts

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at Leerink Partnrs cut their FY2024 earnings estimates for Trevi Therapeutics in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($0.46) per share for the year, down from their previous forecast of ($0.45). The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.39) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics' Q4 2024 earnings at ($0.12) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($1.12) EPS and FY2028 earnings at ($0.69) EPS.

TRVI has been the subject of several other reports. Oppenheimer reaffirmed an "outperform" rating and set a $9.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, March 21st. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday.

Trevi Therapeutics Stock Down 6.5 %

Trevi Therapeutics stock traded down $0.19 during trading on Friday, reaching $2.73. The stock had a trading volume of 89,429 shares, compared to its average volume of 161,620. Trevi Therapeutics has a 52-week low of $0.97 and a 52-week high of $4.00. The business has a 50 day moving average price of $3.03 and a 200 day moving average price of $2.07.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Trevi Therapeutics during the third quarter worth approximately $43,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Trevi Therapeutics in the first quarter valued at about $208,000. Silverarc Capital Management LLC boosted its stake in shares of Trevi Therapeutics by 4.7% during the third quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company's stock worth $2,022,000 after buying an additional 41,491 shares during the period. Opaleye Management Inc. grew its holdings in shares of Trevi Therapeutics by 48.6% during the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company's stock worth $3,397,000 after buying an additional 829,100 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company's stock valued at $7,948,000 after acquiring an additional 60,249 shares during the period. Institutional investors and hedge funds own 95.76% of the company's stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.